Investigating multiple HPV infections and their role in cervical changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the prevalence and clustering of multiple high-risk Human Papillomavirus (HR-HPV) infections in patients with abnormal cervical cytological or histological findings. It aims to understand the epidemiological and methodological factors that contribute to the variability in the detection of these infections. The study will include patients with dysplastic cervical lesions and those diagnosed with Cervical Intraepithelial Neoplasia (CIN) or early-stage invasive cervical cancer. The findings may help clarify the associations between different HPV genotypes and their implications for cervical health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pap smear cytology suggestive of dysplastic cervical lesion worthy of colposcopic evaluation and HPV test
* HPV-related vaginal and/or vulvar lesion
* patients with histological diagnosis after biopsy of Cervical Intraepithelial Neoplasia (CIN) or invasive cervical cancer of stage lower than FIGO staging 1B.

Exclusion Criteria:

* pregnancy
* age less than 18 years
* previous treatment for HPV-related vaginal, vulvar or cervical lesion in the previous 5 years

Where it's running

• Fondazione IRCCS Policlinico San Matteo, SC Ostetricia e Ginecologia 1
  Pavia, Pavia, Italy Recruiting

Study contacts

• Study coordinator: Barbara Gardella, Principal investigator
• Email: b.gardella@smatteo.pv.it
• Phone: +390382503720

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Papillex® for abnormal cervical cells caused by HPV

  This trial will see if taking Papillex® for 180 days helps abnormal cervical cells caused by HPV improve in women aged 25–55 with CIN 1 or 2.

  Recruiting Papillex Inc. · London, Ontario · NCT06979180

• Can people collect their own vaginal sample for HPV testing as well as clinician collection for comparison?

  This study tests whether individuals can correctly use a self-collection device to gather a vaginal sample for high-risk HPV screening and whether the self-collected sample agrees with clinician-collected samples.

  Recruiting at 11 sites Mel Mont Medical · Phoenix, Arizona and 10 other locations · NCT07758140

• Two-probe thermal ablation for cervical precancer in WLWH in South Africa

  This study tests whether using two probes for thermal ablation is safer or more effective than one probe for treating cervical precancer in women living with HIV in South Africa.

  Recruiting Fred Hutchinson Cancer Center · Durban · NCT07645378

• Two-probe thermal ablation for cervical precancer in WLWH in Zimbabwe

  This study tests whether using two TA probes (endocervical and ectocervical) is better than one probe for treating cervical precancer in women living with HIV in Zimbabwe.

  Recruiting Fred Hutchinson Cancer Center · Harare · NCT07645352

• Digital tools to boost HPV vaccination intentions among Nigerian caregivers

  This study tests whether different online content can help Nigerian parents of unvaccinated girls ages 9-14 decide to vaccinate their daughters against HPV.

  Recruiting University of Pennsylvania · Lagos · NCT07498075

• HPV monitoring after chemoradiotherapy for cervical cancer

  This project will test whether HPV detected on cervical swabs and in blood can find cancer recurrence in people with stage IB–IVA cervical cancer after curative chemoradiotherapy.

  Recruiting General University Hospital, Prague · Prague · NCT07493928

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.